Across TCGA pan-cancer cohorts, TMED9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMED9 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMED9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMED9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where TMED9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.608	1.000	.002	5	view →
GBM	DFS	Tertile	All	0.633	0.825	.024	5	view →
LUAD	DFS	Median	III,IV	0.732	0.263	.015	5	view →
PDAC	DFS	Tertile	All	0.343	0.496	.028	4	view →
HNSC	DFS	Median	All	0.830	0.740	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TMED9 tumor-vs-normal RNA expression · all TMED9 data types